Key result
Dabigatran etexilate successfully resolved a left ventricular mural thrombus over 30 days without thromboembolic or bleeding events in a patient with recent subarachnoid hemorrhage.
Case Report (n=1)
No
Dabigatran etixelate successfully treated a left ventricular mural thrombus in a patient with a recent subarachnoid hemorrhage, suggesting direct oral anticoagulants may be a viable alternative to vitamin K antagonists for this indication.
Hypothesis-generating for DOAC use in LV thrombus post-SAH; prospective trials needed before any practice change.
Novel oral anticoagulants may be effective and safe alternatives to conventional treatment for left ventricular (LV) mural thrombus. A case of left ventricular mural thrombus successfully treated with dabigatran etixelate is described, and the rationale for undertaking further systematic evaluation of novel anticoagulants for this indication discussed.
No takes yet. Share an insight, caveat, or question.
Cross et al. (2014) conducted a case report in Left ventricular mural thrombus (n=1). Dabigatran etexilate was evaluated on Resolution of mural thrombus. Dabigatran etexilate successfully resolved a left ventricular mural thrombus over 30 days without thromboembolic or bleeding events in a patient with recent subarachnoid hemorrhage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: